SCHEMBL4677260

SCHEMBL4677260

O=C(O)C(O)=CC(=O)c1cscc1Cc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.41
PTGER4 P35408 1/20 0.38
PTGER2 P43116 1/20 0.38
PTPN1 P18031 4/20 0.37
PTPN2 P17706 1/20 0.37
PTPN6 P29350 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
TSHR P16473 1/20 0.36
HNF4A P41235 1/20 0.36
BCL2 P10415 1/20 0.35
BCL2L1 Q07817 1/20 0.35
CAPN1 P07384 1/20 0.35
KDM6B O15054 1/20 0.34
ALKBH2 Q6NS38 1/20 0.34
ALKBH3 Q96Q83 1/20 0.34
FTO Q9C0B1 1/20 0.34
KDM5B Q9UGL1 1/20 0.34
KDM2A Q9Y2K7 1/20 0.34
KDM3A Q9Y4C1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4677257 1.00 CYP2C9 (0.41) CYP2C9PTGER4PTGER2PTPN1PTPN2
SCHEMBL4671185 0.87 CYP2C9 (0.36) CYP2C9PTGER4PTGER2L3MBTL1
SCHEMBL4673157 0.87 CYP2C9 (0.36) CYP2C9PTGER4PTGER2TSHR
SCHEMBL4676158 0.87 CYP2C9 (0.39) CYP2C9PTGER4PTGER2TSHRKDM6B
SCHEMBL4680966 0.87 SRD5A2 (0.37) CYP2C9PTGER4PTGER2
SCHEMBL4680962 0.87 SRD5A2 (0.37) CYP2C9PTGER4PTGER2
SCHEMBL4671187 0.87 CYP2C9 (0.36) CYP2C9PTGER4PTGER2L3MBTL1
SCHEMBL4673159 0.87 CYP2C9 (0.36) CYP2C9PTGER4PTGER2TSHR
SCHEMBL4676154 0.87 CYP2C9 (0.39) CYP2C9PTGER4PTGER2TSHRKDM6B
SCHEMBL4672682 0.87 HCAR2 (0.40) CYP2C9PTGER4PTGER2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CYP2C9 74/4885PTGER4 4235/4885PTGER2 4764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.